Compare Incyte Corporation (INCY) vs Vanguard Real Estate Index Fund ETF (VNQ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs Vanguard Real Estate Index Fund ETF — how do they compare? Incyte Corporation trades at $112.79 (market cap $22.85B), while Vanguard Real Estate Index Fund ETF trades at $90.73 (market cap $70.80B). The key difference: Vanguard Real Estate Index Fund ETF is far larger — about 3.1× Incyte Corporation's market cap, and Incyte Corporation is trading nearer its 52-week high, Vanguard Real Estate Index Fund ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Incyte Corporation for 33 Days and Vanguard Real Estate Index Fund ETF for 113 Days on average.
| INCY | VNQ | |
|---|---|---|
Market Cap | $22.85B | $70.80B |
Volume | 1,927,029 | 6,073,580 |
Sector | Health | — |
52-Week High | $129.93 | $100.95 |
52-Week Low | $83.80 | $87.00 |
Typical Hold Time | 33 Days | 113 Days |
Enterprise Value | $18.35B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Incyte (INCY) trades at $112.79, down 0.57% on the day, with a bearish technical signal despite recent earnings beats. The company shows strong fundamentals with 2025 revenue of $5.14B and net income of $1.29B, yielding robust profit margins of 92.62% gross and 27.71% net. Recent FDA approval for Atebrioz and pipeline expansion beyond JAKAFI highlight growth initiatives. Valuation metrics appear reasonable with P/E of 14.36 and P/S of 3.98, below sector averages in some cases.
The outlook remains positive with analyst consensus price target of $132.43 implying 17% upside, though near-term pressure exists from Q3 2026 expected EPS loss. Key risks include JAKAFI patent expiration post-2029 and execution on $4B sales target. Institutional sentiment leans bullish with 52% buy ratings, supporting the growth transition story despite technical headwinds.
VNQ trades at $90.65, up 2.21% today, but faces bearish technical signals with 14 sell indicators versus 5 buys. The ETF has declined nearly 10% in the past month amid rising Treasury yields and Federal Reserve rate hikes, eroding its income appeal. Recent institutional buying by State Street Corp and Envestnet suggests some see value at current levels, while news highlights sector-wide REIT pressures and dividend yield comparisons with Treasury bills.
Outlook remains cautious with technical weakness and interest rate sensitivity posing near-term risks. However, contrarian investors may find opportunity in the sector sell-off if long-term real estate fundamentals hold. Key risks include further rate hikes and economic slowdowns affecting property valuations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About Vanguard Real Estate Index Fund ETF
The fund employs an indexing investment approach designed to track the performance of the MSCI US Investable Market Real Estate 25/50 Index, an index made up of stocks of large, mid-size, and small US companies within the real estate sector. The Advisor attempts to replicate the target index by seeking to invest all of its assets in the stocks that make up the index, in order to hold each stock in approximately the same proportion as its weighting in the index. It is non-diversified.
Read more on VNQ →
